Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX +/- SBRT for Borderline Resectable Pancreatic Cancer
NCT06259058Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome injection in pancreatic ductal adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06259058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259058.